Enterprise Value
61.52M
Cash
189.6M
Avg Qtr Burn
-18.26M
Short % of Float
10.77%
Insider Ownership
14.81%
Institutional Own.
74.00%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ORIC-944 (PRC2 inhibitor) Details Prostate cancer | Phase 1b Data readout | |
ORIC-114 (EGFR/HER2 Inhibitor) Details Solid tumor/s, Advanced malignancies | Phase 1b Data readout | |
ORIC-533 (CD73 Inhibitor) Details Multiple myeloma | Phase 1b Data readout | |
Failed Discontinued | ||
Failed Discontinued |